← Back to Awards
NIHNATIONAL CANCER INSTITUTE
Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence
- Institution
- Mayo Clinic Rochester, MN
- Principal investigator
- Keith L. Knutson
- Funding
- $211K
- Duration
- 2009–2026
Moonbase score
Still being scored
Abstract
The overall goal of this project is to perform preclinical and phase II clinical testing of a Th17-induced pulsed dendritic cell vaccine to assess its efficacy in preventing relapse of high grade ovarian cancer in first remission after debulking surgery and platinum-based adjuvant or neoadjuvant chemotherapy.
LOADING MOONBASE SCORE
Questions for Mayo Clinic Rochester
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Mayo Clinic JacksonvilleNot yet scored
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer
Matthew Stephen Block · $639K · 2023–2028
- NIH · Mayo Clinic RochesterNot yet scored
Cancer Immunology and Immunotherapeutics Research Program
Keith L. Knutson · $130K · 1997–2030
- NIH · Mayo Clinic Rochester67
Early Detection of Mild Cognitive Impairment, Alzheimer's Disease and Other Dementias using EHR
Sunghwan Sohn · $610K · 2020–2026